Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunoprecise Antibodies Ltd (TSV:IPA)

N/A UNCHANGED
Last Price Updated: 3:58 PM EST, Nov 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 6.310 (1)
Ask (Size) 6.750 (34)
Prev. Close 6.500
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Performance

More News

Read More
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
From ImmunoPrecise Antibodies
Via Business Wire
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
From ImmunoPrecise Antibodies
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
From ImmunoPrecise Antibodies
Via Business Wire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
From ImmunoPrecise Antibodies
Via Business Wire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
From ImmunoPrecise Antibodies
Via Business Wire
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
From ImmunoPrecise Antibodies
Via Business Wire
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
From ImmunoPrecise Antibodies Ltd
Via Business Wire

Frequently Asked Questions

Is Immunoprecise Antibodies Ltd publicly traded?
Yes, Immunoprecise Antibodies Ltd is publicly traded.
What exchange does Immunoprecise Antibodies Ltd trade on?
Immunoprecise Antibodies Ltd trades on the Toronto Venture Stock Exchange
What is the ticker symbol for Immunoprecise Antibodies Ltd?
The ticker symbol for Immunoprecise Antibodies Ltd is IPA on the Toronto Venture Stock Exchange
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.